1. A Phase I Trial of Ipilimumab (IPI) in Patients (PTS) with Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMAS) Failure. (April 2017) Authors: Zeidan, A.; Knaus, H.; Robinson, T.; Zeidner, J.; Blackford, A.; Duffield, A.; Rizzieri, D.; Frattini, M.; Levy, M.Y.; Schroeder, M.; Ferguson, A.; Sheldon, K.; Dezern, A.; Gojo, I.; Gore, S.; Streicher, H.; Luznik, L.; Smith, B.D. Journal: Leukemia research Issue: Volume 55(2017)Supplement 1 Page Start: S43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗